Timothy Malcolm Caldwell Ph.D.
Principal Investigator, Chemistry, Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals LLC, Department of Chemistry, Lawrence, KS.--Principal Investigator (2017-Present)
Center for World Health and Medicine (CWHM), Saint Louis University, Saint Louis MO--Senior Research Scientist (2015-2017)
AMRI Global LCC, Contractor to Eli Lilly Corp, Indianapolis, IN.--Senior Scientist II (2012-2015)
Deciphera Pharmaceuticals LLC, Department of Chemistry, Lawrence, KS.--Senior Scientist II (2008-2012)
Neurogen Corporation, Department of Chemistry, Branford, CT. --Research Fellow (2001-2008)
I have been a member of thirteen different drug discovery programs. From these programs, eight clinical candidates progressed into clinical trials. One of these candidates (Ripretinib/Qinlock) was approved by the FDA in 2019 for the treatment of gastrointestinal stromal tumors (GIST).